)
Wendell Yang
Wendell Yang is the Founder and President of Imgen BioSciences Inc., bringing over two decades of expertise in T cell receptor (TCR)-based immunotherapy and vaccine development. With a strong foundation in medicine and a PhD in Molecular Biology and Immunology from the University of Queensland, Australia, Dr. Yang has dedicated his career to advancing next-generation T cell therapies.
He has published extensively on TCR-CAR-T technologies in leading peer-reviewed journals and has served as Principal Investigator on multiple research projects funded by the U.S. National Institutes of Health (NIH) and private science foundations. His pioneering work has earned him over three competitive research grants in the CAR-T and TCR-CAR-T fields.
Dr. Yang also holds several international patents and has a pending PCT application for novel innovations in TCR-CAR-T and CAR-T platforms, reinforcing his position as a key innovator in cellular immunotherapy.